Nomad Power Solutions, Inc.

NMAD

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001335105

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $12.7M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data not computable: short runway, distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 31, 2026 237 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026
Last close	$2.57 2026-11-20; market equity $47.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

Company is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company's drug product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 7.9						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(43.3%)	(6.7%)	7.9	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 54.8					
Altman Z double-prime	(9.86)	0.31	62.4	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	3.88x	2.68x	47.3	781	2025-12-31
Growth and financing, sleeve percentile 53.3					
Revenue growth, three-year compound	not computable	9.6%			
four consecutive annual observations are required					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	33.9%			
one or more required annual facts are missing					
Asset growth, three years	31.8%	3.2%	14.4	663	2025-12-31
Net share issuance, one year	332.8%	1.6%	92.2	626	2026-03-31

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 332.8%
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(8.5%)	(1.7%)	44
Distance from 52-week high	(68.2%)	(33.0%)	18
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	2.10	0.29	94
Sales to price	0.00	0.38	2
Composite equity issuance, five years	261.0%	13.5%	95
Relative strength against the sector, log excess return	(0.26)	(0.19)	44
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 16, 2026)
Median daily dollar volume, 63 sessions	$749,697

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$6.1M	2025-12-31	2026-03-31	10-K	26-014052
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.1M	2025-12-31	2026-03-31	10-K	26-014052
3	assets	us-gaap:Assets	$12.7M	2025-12-31	2026-03-31	10-K	26-014052
4	assets	us-gaap:Assets	$1.1M	2024-12-31	2026-03-31	10-K	26-014052
5	current assets	us-gaap:AssetsCurrent	$5.2M	2025-12-31	2026-03-31	10-K	26-014052
6	current liabilities	us-gaap:LiabilitiesCurrent	$1.3M	2025-12-31	2026-03-31	10-K	26-014052
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$58.1M	2025-12-31	2026-03-31	10-K	26-014052
8	operating income	us-gaap:OperatingIncomeLoss	-$5.1M	2025-12-31	2026-03-31	10-K	26-014052
9	book equity	us-gaap:StockholdersEquity	$9.7M	2025-12-31	2026-03-31	10-K	26-014052
10	liabilities	us-gaap:Liabilities	$1.8M	2025-12-31	2026-03-31	10-K	26-014052
11	interest expense	us-gaap:InterestExpense	$9,158	2025-12-31	2026-03-31	10-K	26-014052
12	revenue	us-gaap:Revenues	$200,000	2015-12-31	2016-03-28	10-K	16-008321
13	revenue	us-gaap:Revenues	$0	2013-12-31	2014-03-21	10-K	14-017092
14	revenue	us-gaap:Revenues	$0	2012-12-31	2014-03-21	10-K	14-017092
15	revenue	us-gaap:Revenues	$0	2011-12-31	2013-03-15	10-K	13-015451
16	assets	us-gaap:Assets	$4.3M	2023-12-31	2025-03-24	10-K	25-000208
17	assets	us-gaap:Assets	$5.6M	2022-12-31	2024-03-19	10-K	24-010427
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,617,944	2026-03-31	2026-03-31	10-K	26-014052
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,684,074	2025-03-14	2025-03-24	10-K	25-000208

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.